Skip to main content

Table 4 Serum lipids, lipoproteins and apolipoproteins in the three groups

From: Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis

  HPND (N = 20) HTG (N = 30) HPD (N = 5) P
TC 6.36 ± 2.53 6.75 ± 1.58 8.66 ± 6.86 NS
TG 2.67 (1.85–5.00) 4.81 (2.57–7.83) 13.32 (7.69–29.77) 0.006*
VLDL-Chol 0.78 ± 0.41 0.91 ± 0.49 0.98 ± 0.59 NS
HDL-Chol 1.01 ± 0.47 0.91 ± 0.39 0.39 ± 0.13 0.01*
LDL-Chol 3.21 ± 1.40 3.39 ± 1.32 1.45 ± 1.27 0.01 *
VLDL-TG 1.27 (1.02–1.81) 1.39 (1.07–2.49) 1.94 (1.45–3.22) NS
HDL-TG 0.35 (0.28–0.46) 0.32 (0.25–0.46) 0.21 (0.14–0.44) NS
LDL-TG 0.56 (0.39–0.64) 0.53 (0.43–0.69) 0.59 (0.46–1.00) NS
Chylo-Chol 2.95 ± 3.34 2.22 ± 1.58 5.90 ± 7.55 NS
Chylo-TG 3.31 (2.52–7.40) 3.48 (2.21–6.60) 8.49 (5.2–23.81) 0.02**
Apo A-I 1.14 ± 0.29 1.11 ± 0.28 0.54 ± 0.17 <0.001 *
Apo B-100 0.98 ± 0.27 0.98 ± 0.25 0.56 ± 0.37 0.007 *
Apo CII 0.11 ± 0.06 0.13 ± 0.07 0.09 ± 0.05 NS
Apo CIII 0.17 ± 0.07 0.20 ± 0.09 0.19 ± 0.05 NS
Apo E 0.07 ± 0.04 0.11 ± 0.06 0.14 ± 0.03 0.005 *
CIII/CII 2 ± 3 1.7 ± 0.7 5 ± 7 NS
LPLactivity
(mU/ml)
82 ± 34 95 ± 41 0.4 ± 0.5 <0.001 *
HL-activity
(mU/ml)
179 ± 95 195 ± 86 107 ± 47 NS
Posth-LPLmass
(ng/ml)
365 ± 164 422 ± 190 58 ± 27 <0.001*
Preh-LPLmass
(ng/ml)
19 ± 10 22 ± 14 17 ± 12 NS
  1. Data are shown as mean ± SD unless Tg shown as median (IQ range). HPD: patient with LPL deficiency. HPND: HP without LPL deficiency. TC: total cholesterol. TG: triglyceride. *: Differences between HPD and the others groups.** Differences between HPD and HTG group.